-
Azenta, Inc. (AZTA) PT Lowered to $30 at TD Cowen
-
Azenta, Inc. (AZTA) Misses Q1 EPS by 5c
-
Azenta agrees to sell B Medical Systems unit for $63 million
-
Needham Reiterates Buy Rating on Azenta, Inc. (AZTA)
-
Azenta, Inc. (AZTA) PT Raised to $45 at Raymond James
-
Nephron Upgrades Azenta, Inc. (AZTA) to Hold
-
Azenta, Inc. (AZTA) PT Raised to $42 at Needham
-
Azenta, Inc. (AZTA) Tops Q4 EPS by 2c, Beats on Revenue; Offers Guidance
-
Jefferies Upgrades Azenta, Inc. (AZTA) to Buy
-
Raymond James Upgrades Azenta, Inc. (AZTA) to Outperform
-
Azenta, Inc. (AZTA) PT Lowered to $33 at Evercore ISI
-
Azenta, Inc. (AZTA) Tops Q3 EPS by 6c
-
Azenta, Inc. (AZTA) Misses Q2 EPS by 3c
-
TD Cowen Starts Azenta, Inc. (AZTA) at Hold
-
Azenta, Inc. (AZTA) PT Raised to $52 at Jefferies
-
Azenta, Inc. (AZTA) PT Raised to $59 at Needham
-
Azenta, Inc. (AZTA) Tops Q1 EPS by 3c ; Provides Outlook
-
Azenta, Inc. (AZTA) Appoints Dipal Doshi to its Board
-
Flex (FLEX) to Join S&P MidCap 400; Azenta (AZTA) and Concentra Group Holdings (CON) to Join S&P SmallCap 600
-
Azenta, Inc. (AZTA) PT Lowered to $55 at Needham
-
Azenta, Inc. (AZTA) PT Lowered to $48 at Evercore ISI
-
Azenta, Inc. (AZTA) Tops Q4 EPS by 8c
-
Azenta, Inc. (AZTA) to Sell B Medical Systems, Appoints Lawrence Y. Lin as CFO
-
Azenta, Inc. (AZTA) Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
-
Azenta, Inc. (AZTA) Announces Appointment Of John P. Marotta As CEO
-
Azenta, Inc. (AZTA) Tops Q3 EPS by 9c ; Offers Guidance

